FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics and concerns sulfonamide compounds for the treatment and/or prevention of tumors. For this purpose, a pharmaceutical composition is developed, containing the effective amount of a sulfonamide compound represented by the formula (I), where X1 is an oxygen atom; X2 is an oxygen atom; X3 is -NH-; X4 is a hydrogen atom; R1 is -C(R11)(R12)-; one of R11 and R12 is a hydrogen atom, and the other is a methyl group; R2 is a phenyl group having R21 as a substituent; R21 is a halogen atom or C1-C6 alkyl group (when two or more of R21 are present, R21 are the same or different from each other); R3 is a phenyl group having R31 as a substituent, or a chromanyl group having Rc as a substituent; R31 is a halogen atom or an aminocarbonyl group (when two or more of R31 are present, R31 are the same or different from each other ); Rc is a halogen atom, a hydroxy group, or C1-C6 alkyl group (when two or more of Rc are present, Rc are the same or different from each other), and R4 is a hydrogen atom; or its pharmaceutically acceptable salt and at least another antitumor agent. An agent for enhancing the antitumor effect of another antitumor agent, an antitumor agent for the treatment of a cancer patient receiving another antitumor agent, a sulfonamide compound, and methods for the treatment and/or prevention of cancer are also disclosed.
EFFECT: resulting compounds have the activity of inhibiting ribonucleotide reductase (RNR) and enhance the antitumor effect when used together with another compound having an antitumor effect.
36 cl, 4 dwg, 51 tbl, 355 ex
Title | Year | Author | Number |
---|---|---|---|
SULPHONAMIDE COMPOUND OR SALT THEREOF | 2017 |
|
RU2732572C2 |
SULFONAMIDE COMPOUNDS AND THEIR USE | 2018 |
|
RU2781383C2 |
HETEROAROMATIC MODULATORS OF RETINOL-BOUND ORPHAN GAMMA RECEPTOR | 2017 |
|
RU2771280C2 |
NOVEL PHENYL PYRROLE DERIVATIVE | 2009 |
|
RU2470917C2 |
CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
2,4-PYRIMIDINDIAMINE COMPOUNDS HAVING EFFECT IN CASE OF AUTOIMMUNE DISORDERS | 2004 |
|
RU2356901C2 |
DIAMINE DERIVATIVES | 2003 |
|
RU2333203C2 |
DERIVATIVES OF HYDROXAMIC OR CARBOXYLIC ACID AND PHARMACEUTICAL OR VETERINARY COMPOSITION ON SAID | 1995 |
|
RU2136657C1 |
METHODS FOR TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH USE OF 2,4-PYRIMIDINEDIAMINE | 2013 |
|
RU2659777C2 |
CYCLOALKANE DERIVATIVE | 2013 |
|
RU2635354C2 |
Authors
Dates
2022-04-22—Published
2018-11-28—Filed